Miller KD, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85. https://doi.org/10.3322/caac.21565.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.

Article  PubMed  Google Scholar 

Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:1–11. https://doi.org/10.3389/fonc.2014.00064.

Article  Google Scholar 

Markman B, Atzori F, Pérez-García J, Tabernero J, Baselga J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol. 2009;21(4):683–91. https://doi.org/10.1093/annonc/mdp347.

Article  PubMed  Google Scholar 

Yip PY. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell Lung cancer. Transl Lung Cancer Res. 2015;4(2):165–76. https://doi.org/10.3978/j.issn.2218-6751.2015.01.04.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Narayanankutty A. PI3K/ Akt/ mTOR pathway as a therapeutic target for colorectal cancer: a review of preclinical and clinical evidence. Curr Drug Targets. 2019;20(12):1217–26. https://doi.org/10.2174/1389450120666190618123846.

Article  CAS  PubMed  Google Scholar 

Zhao W, Qiu Y, Kong D. Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. Acta Pharm Sin B. 2017;7(1):27–37. https://doi.org/10.1016/j.apsb.2016.07.006.

Article  PubMed  Google Scholar 

Huang Z, et al. Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review. Futur Oncol. 2015;11(11):1687–99. https://doi.org/10.2217/fon.15.70.

Article  CAS  Google Scholar 

Yang F, Gao JY, Chen H, Du ZH, Zhang XQ, Gao W. Targeted inhibition of the phosphoinositide 3-kinase impairs cell proliferation, survival, and invasion in colon Cancer. Onco Targets Ther. 2017;10:4413–22. https://doi.org/10.2147/OTT.S145601.

Article  PubMed  PubMed Central  Google Scholar 

Li C, Xin P, Xiao H, Zheng Y, Huang Y, Zhu X. The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells. Cancer Cell Int. 2015;15(1):1–9. https://doi.org/10.1186/s12935-015-0213-1.

Article  CAS  Google Scholar 

Link W, et al. Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J Biol Chem. 2009;284(41):28392–400. https://doi.org/10.1074/jbc.M109.038984.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37(2):112–9. https://doi.org/10.1016/j.clinbiochem.2003.10.014.

Article  CAS  PubMed  Google Scholar 

Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38(12):1103–11. https://doi.org/10.1016/j.clinbiochem.2005.08.008.

Article  CAS  PubMed  Google Scholar 

Bu Z, Ji J. Therapeutic implications of mTOR inhibitors in the treatment of gastric cancer. Curr Cancer Drug Targets. 2013;13:121–5. https://doi.org/10.2174/1568009611313020002.

Article  CAS  PubMed  Google Scholar 

Chen J. Potential value and limitation of dual inhibitors of PI3K and mTOR in the treatment of cancer. Curr Cancer Drug Targets. 2013;13(2):117–20. https://doi.org/10.2174/1568009611313020001.

Article  CAS  PubMed  Google Scholar 

Cho DC, Mier JW. Dual inhibition of PI3-Kinase and mTOR in renal cell carcinoma. Curr Cancer Drug Targets. 2013;13:126–42. https://doi.org/10.2174/1568009611313020003. no. 2.

Article  CAS  PubMed  Google Scholar 

Elfiky AA, Jiang Z. The PI3 kinase signaling pathway in prostate cancer. Curr Cancer Drug Targets. 2013;13:157–64. https://doi.org/10.2174/1568009611313020005.

Article  CAS  PubMed  Google Scholar 

Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(6):1075–83. https://doi.org/10.1200/JCO.2009.25.3641.

Article  CAS  Google Scholar 

Fumarola C, Bonelli MA, Petronini PG, Alfieri RR. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol. 2014;90(3):197–207. https://doi.org/10.1016/j.bcp.2014.05.011.

Article  CAS  PubMed  Google Scholar 

Moon DG, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol. 2014;45(3):1027–35. https://doi.org/10.3892/ijo.2014.2505.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garcia JA, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther. 2008;7(6):1347–54. https://doi.org/10.1158/1535-7163.MCT-07-2408.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cebulla J, et al. MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity. Br J Cancer. 2015;112(3):504–13. https://doi.org/10.1038/bjc.2014.628.

Article  CAS  PubMed  Google Scholar 

Wu D, et al. p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma. Oncotarget. 2016;7(24):36539–50. https://doi.org/10.18632/oncotarget.9282.

Article  PubMed  PubMed Central  Google Scholar 

Segatto I, et al. p70S6 kinase mediates breast cancer cell survival in response to surgical wound fluid stimulation. Mol Oncol. 2014;8(3):766–80. https://doi.org/10.1016/j.molonc.2014.02.006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J. 2008;415(3):333–44. https://doi.org/10.1042/BJ20081056.

Article  CAS  PubMed  Google Scholar 

Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307(5712):1098–101. https://doi.org/10.1126/science.1106148.

Article  CAS  PubMed  Google Scholar 

Roy HK, et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinog. 2002;23(1):201–5. https://doi.org/10.1093/carcin/23.1.201.

Article  CAS  Google Scholar 

Cumhur VAS, Fak TIP, Anab H. “PI3K / AKT / MTOR YOLAK İNHİBİYONU İLE ANTİOKSİDAN,” 2021.

Hill R, et al. A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes. Breast Cancer Res. 2014;16(1):1–15. https://doi.org/10.1186/s13058-014-0482-y.

Article  CAS  Google Scholar 

Link W, et al. Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J Biol Chem. 2009;284:28392–400. https://doi.org/10.1074/jbc.M109.038984.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kerr JF, Wyllie AH. Currie AR apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–57. https://doi.org/10.1038/bjc.1972.33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. ” Int Rev Cytol. 1980;68:251–306. https://doi.org/10.1016/s0074-7696(08)62312-8.

Article  CAS  PubMed  Google Scholar 

Wyllie AH. Apoptosis (the 1992 frank rose memorial lecture). Br J Cancer. 1993;67(2):205–8. https://doi.org/10.1038/bjc.1993.40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol. 1995;146(1):3–15.

CAS  PubMed  PubMed Central  Google Scholar 

Rudin CM, Thompson CB. Apoptosis and disease: regulation and clinical relevance of programmed cell death. ” Annu Rev Med. 1997;48:267–81. https://doi.org/10.1146/annurev.med.48.1.267.

Article  CAS  PubMed  Google Scholar 

Tait JF, Gibson D, Fujikawa K. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J Biol Chem. 1989;264(14):7944–9.